Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Jun 1.

Published in final edited form as: Clin Cancer Res. 2020 Sep 17;26(23):6112–6121. doi: 10.1158/1078-0432.CCR-20-1696

Table 4:

Pexidartinib pharmacodynamics: Serum cytokine analysis fold change from Day 1

	14–15 Days from C1			27–29 Days from C1
Cytokine	N	P^*	Med. Fold Change (95% CI)	N	P^*	Med. Fold Change (95% CI)
IL-10	12	0.021	1.25 (1.11, 1.44)	8	0.64	1.22 (0.81, 1.30)
IL-12p70	12	0.79	0.92 (0.80, 1.25)	8	0.023	0.86 (0.66, 1.05)
IL-6	12	0.85	0.91 (0.78, 1.34)	8	0.95	0.98 (0.64, 2.39)
MCP-1	12	0.003	1.28 (1.01, 1.56)	8	0.023	1.27 (1.11, 1.54)
M-CSF	12	0.0005	3.70 (2.31, 5.24)	8	0.008	4.52 (2.40, 13.3)

^*

Two-tailed unadjusted signed rank test p-value for Mu=1